456 related articles for article (PubMed ID: 33055258)
1. Gram-Negative Taxa and Antimicrobial Susceptibility after Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.
Steed DB; Wang T; Raheja D; Waldman AD; Babiker A; Dhere T; Kraft CS; Woodworth MH
mSphere; 2020 Oct; 5(5):. PubMed ID: 33055258
[TBL] [Abstract][Full Text] [Related]
2. Fecal Microbiota Transplantation Increases Colonic IL-25 and Dampens Tissue Inflammation in Patients with Recurrent Clostridioides difficile.
Jan N; Hays RA; Oakland DN; Kumar P; Ramakrishnan G; Behm BW; Petri WA; Marie C
mSphere; 2021 Oct; 6(5):e0066921. PubMed ID: 34704776
[TBL] [Abstract][Full Text] [Related]
3. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).
Minkoff NZ; Aslam S; Medina M; Tanner-Smith EE; Zackular JP; Acra S; Nicholson MR; Imdad A
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD013871. PubMed ID: 37096495
[TBL] [Abstract][Full Text] [Related]
4. Long-term durability and safety of fecal microbiota transplantation for recurrent or refractory Clostridioides difficile infection with or without antibiotic exposure.
Lee CH; Chai J; Hammond K; Jeon SR; Patel Y; Goldeh C; Kim P
Eur J Clin Microbiol Infect Dis; 2019 Sep; 38(9):1731-1735. PubMed ID: 31165961
[TBL] [Abstract][Full Text] [Related]
5. A microbial consortium alters intestinal
Rooney AM; Cochrane K; Fedsin S; Yao S; Anwer S; Dehmiwal S; Hota S; Poutanen S; Allen-Vercoe E; Coburn B;
mBio; 2023 Aug; 14(4):e0348222. PubMed ID: 37404011
[TBL] [Abstract][Full Text] [Related]
6. Durable Long-Term Bacterial Engraftment following Encapsulated Fecal Microbiota Transplantation To Treat Clostridium difficile Infection.
Staley C; Kaiser T; Vaughn BP; Graiziger C; Hamilton MJ; Kabage AJ; Khoruts A; Sadowsky MJ
mBio; 2019 Jul; 10(4):. PubMed ID: 31337728
[TBL] [Abstract][Full Text] [Related]
7. Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile Infection following Fecal Microbiota Transplantation.
Staley C; Kelly CR; Brandt LJ; Khoruts A; Sadowsky MJ
mBio; 2016 Dec; 7(6):. PubMed ID: 27999162
[TBL] [Abstract][Full Text] [Related]
8. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent
Mullish BH; McDonald JAK; Pechlivanis A; Allegretti JR; Kao D; Barker GF; Kapila D; Petrof EO; Joyce SA; Gahan CGM; Glegola-Madejska I; Williams HRT; Holmes E; Clarke TB; Thursz MR; Marchesi JR
Gut; 2019 Oct; 68(10):1791-1800. PubMed ID: 30816855
[TBL] [Abstract][Full Text] [Related]
9. Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway.
Monaghan T; Mullish BH; Patterson J; Wong GK; Marchesi JR; Xu H; Jilani T; Kao D
Gut Microbes; 2019; 10(2):142-148. PubMed ID: 30183484
[TBL] [Abstract][Full Text] [Related]
10. Alteration of gut microbial composition associated with the therapeutic efficacy of fecal microbiota transplantation in Clostridium difficile infection.
Lee PC; Chang TE; Wang YP; Lee KC; Lin YT; Chiou JJ; Huang CW; Yang UC; Li FY; Huang HC; Wu CY; Huang YH; Hou MC
J Formos Med Assoc; 2022 Sep; 121(9):1636-1646. PubMed ID: 34836663
[TBL] [Abstract][Full Text] [Related]
11. Fecal microbiota transplantation for treatment of patients with recurrent
Voth E; Khanna S
Expert Rev Anti Infect Ther; 2020 Jul; 18(7):669-676. PubMed ID: 32266848
[TBL] [Abstract][Full Text] [Related]
12. Faecal microbiota transplantation in the treatment of recurrent intestinal Clostridioides difficile infection - a ten-year single-center experience.
Pipek B; Valentová H; Fojtík P; Urban O
Cas Lek Cesk; 2022; 161(3-4):126-130. PubMed ID: 36100450
[TBL] [Abstract][Full Text] [Related]
13. Recovery of the gut microbiome following fecal microbiota transplantation.
Seekatz AM; Aas J; Gessert CE; Rubin TA; Saman DM; Bakken JS; Young VB
mBio; 2014 Jun; 5(3):e00893-14. PubMed ID: 24939885
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for Treatment of Recurrent Clostridioides difficile Infection.
Perler BK; Chen B; Phelps E; Allegretti JR; Fischer M; Ganapini V; Krajiceck E; Kumar V; Marcus J; Nativ L; Kelly CR
J Clin Gastroenterol; 2020 Sep; 54(8):701-706. PubMed ID: 32011405
[TBL] [Abstract][Full Text] [Related]
15. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in the Elderly: Long-Term Outcomes and Microbiota Changes.
Girotra M; Garg S; Anand R; Song Y; Dutta SK
Dig Dis Sci; 2016 Oct; 61(10):3007-3015. PubMed ID: 27447476
[TBL] [Abstract][Full Text] [Related]
16. Durability and Long-term Clinical Outcomes of Fecal Microbiota Transplant Treatment in Patients With Recurrent Clostridium difficile Infection.
Mamo Y; Woodworth MH; Wang T; Dhere T; Kraft CS
Clin Infect Dis; 2018 May; 66(11):1705-1711. PubMed ID: 29272401
[TBL] [Abstract][Full Text] [Related]
17. Predicting recurrence of Clostridium difficile infection following encapsulated fecal microbiota transplantation.
Staley C; Kaiser T; Vaughn BP; Graiziger CT; Hamilton MJ; Rehman TU; Song K; Khoruts A; Sadowsky MJ
Microbiome; 2018 Sep; 6(1):166. PubMed ID: 30227892
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.
Vaughn BP; Fischer M; Kelly CR; Allegretti JR; Graiziger C; Thomas J; McClure E; Kabage AJ; Khoruts A
Clin Gastroenterol Hepatol; 2023 May; 21(5):1330-1337.e2. PubMed ID: 36126907
[TBL] [Abstract][Full Text] [Related]
19. Fecal microbiota transplantation for recurrent Clostridioides difficile infection in patients with concurrent ulcerative colitis.
Porcari S; Severino A; Rondinella D; Bibbò S; Quaranta G; Masucci L; Maida M; Scaldaferri F; Sanguinetti M; Gasbarrini A; Cammarota G; Ianiro G
J Autoimmun; 2023 Dec; 141():103033. PubMed ID: 37085337
[TBL] [Abstract][Full Text] [Related]
20. Depletion of butyrate-producing microbes of the Firmicutes predicts nonresponse to FMT therapy in patients with recurrent
Tian H; Cui J; Ye C; Zhao J; Yang B; Xu Y; Ji S; Wang L; Lv X; Ma C; Zhou S; Li N; Wang X; Qin H; Chen Q
Gut Microbes; 2023; 15(1):2236362. PubMed ID: 37469017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
